IMUGENE FPOIMUGENE FPOIMUGENE FPO

IMUGENE FPO

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪95.53 M‬AUD
−0.600AUD
‪−149.68 M‬AUD
0.00AUD
‪187.83 M‬
Beta (1Y)
1.17

About IMUGENE FPO


CEO
Leslie Chong
Headquarters
Sydney
Founded
1986
ISIN
AU000000IMU9
FIGI
BBG000BZ3TD8
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.

Check out other big names from the same industry as IMU.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange IMUGENE FPO stocks are traded under the ticker IMU.
IMU stock has risen by 27.27% compared to the previous week, the month change is a ‪3.07 K‬% rise, over the last year IMUGENE FPO has showed a 833.33% increase.
IMU reached its all-time high on Jun 30, 1994 with the price of 7.359 AUD, and its all-time low was 0.004 AUD and was reached on Jun 17, 2013. View more price dynamics on IMU chart.
See other stocks reaching their highest and lowest prices.
IMU stock is 16.67% volatile and has beta coefficient of 1.17. Track IMUGENE FPO stock price on the chart and check out the list of the most volatile stocks — is IMUGENE FPO there?
Today IMUGENE FPO has the market capitalization of ‪91.14 M‬, it has decreased by −97.25% over the last week.
Yes, you can track IMUGENE FPO financials in yearly and quarterly reports right on TradingView.
IMUGENE FPO is going to release the next earnings report on Aug 27, 2025. Keep track of upcoming events with our Earnings Calendar.
IMU earnings for the last half-year are −0.22 AUD per share, whereas the estimation was −0.34 AUD, resulting in a 34.75% surprise. The estimated earnings for the next half-year are −0.34 AUD per share. See more details about IMUGENE FPO earnings.
IMU net income for the last half-year is ‪−48.34 M‬ AUD, while the previous report showed ‪−80.97 M‬ AUD of net income which accounts for 40.30% change. Track more IMUGENE FPO financial stats to get the full picture.
No, IMU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMUGENE FPO stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMUGENE FPO technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMUGENE FPO stock shows the strong buy signal. See more of IMUGENE FPO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.